Tests electrical eye stimulation for vision in glaucoma patients
Tests a device sending mild electrical current through the eye in adults with glaucoma.
Plain-language title generated from the registry record
Registry title: Electrical Stimulation for Vision Neuroenhancement in Glaucoma
Key facts
- Where
- Palo Alto, United StatesSee the site
Where in United States
- Byers Eye Institute at Stanford UniversityPalo Alto, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Stanford University
- Trial code
- NCT06685211
- Record updated
- 9 October 2026
- Original description
The purpose of the study is to evaluate the efficacy, transorbital alternating current stimulation (rtACS) using the EYETRONIC for the treatment in patients with glaucoma.Read full original descriptionShow less
A Randomized, Sham Controlled, Masked Study to Evaluate the Efficacy of Alternating Current Stimulation Using the Eyetronic System for the Treatment of Glaucoma
The purpose of the study is to evaluate the efficacy, transorbital alternating current stimulation (rtACS) using the EYETRONIC for the treatment in patients with glaucoma.
Inclusion: Participant must be at least 18; Participant must has the ability to comply with the requirements of the study and complete the schedule of events (SOE); Participant's clinical diagnosis must be consistent with primary open angle glaucoma (including but not limited to normal tension, low tension or general open angle) characterized by the following features: Mean deviation (MD) worse than -6 but better than -20 on reliable Humphrey Visual Field 24-2 testing; Participant's eye pressure must be clinically stable, with IOP < 18; If a participant has two eyes meeting study criteria, the worse eye as determined by visual field index (VFI) or patient preference, will be deemed includable. If both eyes qualify and have the same VFI, the patient may choose which eye they are willing to enter, or else a randomization procedure will assign one eye to the study; Participant must understand and sign the informed consent. If the participant's vision is impaired to the point where he/she cannot read the informed consent document, the document will be read to the participant in its entirety.
Exclusion: Participant has a requirement of acyclovir and/or related products during study duration. To be eligible for this study, the participant must discontinue use of these products prior to enrollment and must not continue with the products until after they have completed the study; Participant is receiving systemic steroids or other immunosuppressive medications; Participant is currently participating in or has within the last 3 months participated in any other clinical trial of a drug by ocular (if in the study eye) or systemic administration; Patients abusing drugs or alcohol; Participant has a history of ocular herpes zoster; Participant has uveitis or other ocular inflammatory disease; Participant has, in the opinion of the investigator, any physical or mental condition that would increase the risk of participation in the study or may interfere with the study procedures, evaluations and outcome assessments; Patients with opened skull, after trepanation or with heart and brain pacemaker; Patients with recent history of epileptic seizure; Participant is unable to comply with study procedures or follow-up visits; Participant has evidence of corneal opacification or lack of optical clarity; Participant is pregnant or lactating; Patients with implanted intracranial metals such as clippings, coilings, ventriculo-peritoneal shunts, endoprosthesis etc; Patients with any skin damage in the area of electrode placement; Children and comatose patients; Patients with uncontrolled high levels of blood pressure (<160 mmHg) or uncontrolled high levels of intraocular pressure (<27 mmHg).